Transgene to invest in €10m Sanofi immunotherapy plant
This article was originally published in Scrip
Executive Summary
Sanofi has buddied up with fellow French firm Transgene to build a new facility for manufacturing immunotherapy products. Each of the two companies will invest €5 million but the new industrial platform will remain Sanofi's exclusive property, and be based at its Genzyme Polyclonals antibody production site in Lyon, France.